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Abstract
Purpose: Expression of human chorionic gonadotropin beta subunit by cancers is extensively documented, yet
regulation of the multiple genes that can code for this protein is poorly understood. The aim of the study was to
examine the mechanisms regulating CGB gene expression in ovarian cancer.
Methods: Expression of CGB genes and SP1, SP3, TFAP2A transcription factor genes was evaluated by RT-qPCR. The
methylation status of CGB genes promoter regions was examined by methylation-specific PCR.
Results: mRNA arising from multiple CGB genes was detected in both ovarian control and malignant tissues. However,
expression of CGB3–9 genes was shown to be significantly higher in malignant than healthy ovarian tissues. CGB1 and
CGB2 transcripts were shown to be present in 20% of ovarian cancers, but were not detected in any of the control
samples. Malignant tissues were characterized by DNA demethylation of CGB promoter regions. In ovarian cancer CGB
expression positively correlated with TFAP2A transcripts level and expression of TFAP2A transcription factor was
significantly higher in cancer than in control tissues. In contrast SP3 expression level was significantly lower in
ovarian tumours than in control ovarian tissue.
Conclusions: In ovarian cancers increased expression of human chorionic gonadotropin beta subunit is
associated with demethylation of CGB promoter regions. CGB3–9 expression level strongly correlates with
expression of the TFAP2A transcription factor. Presence of mRNA arising from CGB1 and CGB2 genes appears
to be a unique feature of a subset of ovarian cancers.
Keywords: Human chorionic gonadotropin beta subunit, DNA methylation, Gene expression regulation, AP2
transcription factor, Ovarian cancer
Background
Human chorionic gonadotropin (hCG) is a hormone
known for its significant role in sustaining pregnancy
and survival of the foetus. In particular, it supports
decidualization of the endometrium and embryo im-
plantation. More recent studies suggest that hCG plays
an important role in human placental angiogenesis and
maternal immunosuppression as well as immunotoler-
ance of the embryo [1–3].
It has also been shown that expression of hCG, in
particular its free beta subunit (hCGβ), is detected in
30–60% of tumours of different origin [4]. Many studies
have demonstrated that both hCG and hCGβ promote
survival of cancer cells via regulation of cell proliferation,
angiogenesis, and apoptosis [1–3, 5–7]. Furthermore,
hCGβ secretion by a tumour is strongly associated with
metastasis, resistance to therapy, which are consequently
linked to poor prognosis [7]. Recently it was reported that
hCGβ induces transformation of ovarian surface epithelial
cells. Specifically the free hCG beta subunit has been
shown to regulate the epithelial-mesenchymal transition
process and support migration and invasion of cancer cells
[8]. CGB overexpression by tumours was shown also to
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promote valculogenic mimicry – a rate-limiting step in
metastasis of ovarian cancer [9].
Although the associations between ectopic expression
of hCG/hCGβ and carcinogenesis are now established,
the exact molecular mechanisms behind regulation of
CGB genes that encode for this hormone’s beta-subunit
remain unclear [10–17].
The beta subunit of hCG is encoded by a group of
highly homologous genes (marked CGB1–CGB9) but
the expression of individual CGB genes is uneven. Ana-
lysis of mRNA derived from placentas and cancer tissues
pointed to a twenty fold higher transcriptional activity of
CGB5 compared to CGB3 or CGB8 [18, 19].
During pregnancy CGB expression is dependent on
epigenetic changes as well as expression of tissue-specific
transcription factors [10–17, 20]. Studies have shown that,
in placental tissues, regions of DNA encoding the CGB
gene cluster are hypo-methylated [13]. This was also true
of choriocarcinoma samples. Moreover it was demon-
strated that methylation sensitive allelic polymorphism in
CGB5 gene promoter regions, may be associated with a
higher susceptibility for miscarriage [10–12]. Our recent
study also confirmed that changes in CGB genes expres-
sion, caused by deregulation of epigenetic mechanisms, is
associated with increased risk of early pregnancy loss [13].
Another aspect of CGB expression regulation by the
placenta is the dependency on the access to selected
transcription factors: ETS-2, SP1, SP3, AP2, OCT3/4,
PPARγ, P53 and MTA3 and their binding capacity [20–26].
However, AP2, SP1 and SP3, are believed to be the key reg-
ulators of basal CGB transcription in placental trophoblast
cells [20–26]. In fact, we have previously shown that, during
pregnancy, expression of CGB genes strongly correlates
with expression of the TFAP2A gene, encoding the AP2
transcription factor [13].
In this study we examined the hypothesis that, similar
to placenta, CGB expression by ovarian cancers is associ-
ated with methylation alterations of the CGB gene cluster,
along with changes in the level of the three key transcrip-
tion factors: AP2, SP1 and SP3.
Methods
Sample collection
Ovarian cancer tissue samples were collected from 19
patients treated by surgery at the Department of Gynaeco-
logic Oncology, Poznan University of Medical Sciences,
Poland. The histological subtypes of ovarian carcinomas
were: 12 serous, 2 endometrioid, 2 undifferentiated, 2 solid
appendages, 1 mucinous. UICC histological grading of the
subtypes of ovarian carcinomas was as follows: G1, n = 1;
G2, n = 6 and G3, n = 12 stage (Table 1).
A control group of samples consisted of 12 ovarian tissues
that lacked cancerous changes, as evaluated by a clinical pa-
thologist’s macroscopic and microscopic examination. These
control tissues were obtained from postmenopausal patients
who underwent total hysterectomy with additional oophor-
ectomy due to benign myometrial and endometrial lesions.
The study was approved by the ethics review board of
Poznan University of Medical Sciences (Resolution No:
748/08) and all patients participated after written informed
consent.
Tissue samples obtained during surgery were stored in
RNAlater (Thermo Fisher Scientific, Waltham, MA,
USA) at − 80 °C.
RT-qPCR assays
Total RNA was isolated from 100 to 300 mg of tissue
homogenized in 1 mL of TriPure Isolation Reagent
(Roche Diagnostics, Mannheim, Germany) according to
the manufacturer’s protocol. RNA concentration and
quality was determined spectrophotometrically and by
eletrophoresis. The material was stored at − 80 °C for
further analysis.
One microgram of total RNA was used as template for
reverse transcription using the oligo (dT)10 primer and
Transcriptor Reverse Transcriptase (Roche Diagnostics,
Mannheim, Germany) according to the manufacturer’s
protocol.
RT-qPCR assays were designed to assess the expression
level of analyzed genes encoding human chorionic go-
nadotropin beta subunit as well as SP1, SP3 and TFAP2A
transcription factors. CGB genes were studied in two
groups: 1) genes previously considered as pseudogenes:
CGB1 and CGB2 (CGB1–2), and 2) the most transcrip-
tionally active genes: CGB3/CGB9, CGB5, CGB6/CGB7,
CGB8 (CGB3–9). Hydrolysis TaqMan probes and primers
used in RT-qPCR assays are presented in Table 2.
RT-qPCR was performed using LightCycler TaqMan
Master or LightCycler FastStart DNA Master SYBR
Green I kit (Roche Diagnostics, Mannheim, Germany)
on a LightCycler 2.0 Instrument (Roche Diagnostics,
Mannheim, Germany). Assays were performed according
to the manufacturer’s protocols.
PCR efficiencies were calculated from standard curves,
which were generated using serial dilutions of a cDNA
library obtained from term placenta. Relative expression
of genes was normalized against hypoxanthine-guanine
phosphoribosyltransferase 1 (HPRT) expression. Data
was assembled using the software 4.05 dedicated for the
LightCycler 2.0.
Methylation-specific polymerase chain reaction for CGB
promoter
DNA was extracted from 50 to 300 mg of tissue samples
using AxyPrep Multisource Genomic DNA Miniprep Kit
(Axygen, Unin City, CA, USA). DNA concentration and
quality was determined using NanoDrop ND-1000
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spectrophotometer (Thermo Fisher Scientific, Waltham,
MA, USA) and by electrophoresis.
One microgram of genomic DNA was converted with
bisulfite and cleaned using EpiTect Bisulfite Kit (Qiagen,
Hilden, Germany). The prepared material was stored
at − 20 °C for further analysis. The quality of the con-
version was verified by PCR using methylation inde-
pendent primers for death associated kinase 1 gene,
DAPK1 (Zymo Research, Irvine, CA, USA) (Table 3).
The method used for the assessment of methylation
level of CGB genes was methylation specific PCR (MSP).
The analyzed allelic CGB genes were divided into two
groups. The first included CGB3/CGB9, CGB5 and
CGB8 and the second consisted of CGB1 and CGB2.
Primers used in the study were designed to cover the
consensus promoter regions of genes CGB3–9 and
CGB1–2 respectively. Each set of primers consisted of
two pairs: one designed to bind the methylated form of
the given sequence (CGB1–2_ M, CGB3–9_ M) and
the other to bind the non-methylated sequence
(CGB1–2_ NM, CGB3–9_NM). Primer sequences and
reactions conditions are presented in Table 3.
After amplification, the PCR products were separated
by electrophoresis in 2% agarose gel stained with eth-
idium bromide (0.5 μg/ml). Images were collected and
analyzed with G:BOX iChemi, model XL1.4 (Syngene,
Bangalore, India).
Statistical analysis
All data were analyzed using Statistica 13.3 software
package (StatSoft, Kraków, Poland). As the data was not
normally distributed non-parametric statistics were ap-
plied. Associations between variables in the studied
groups of ovarian tumours and control ovarian tissues
was assessed using Spearman’s rank correlations. The
differences between the two groups were analyzed using
Mann-Whitney U tests. p < 0.05 was considered to indi-
cate statistical significance.
Results
Expression levels of CGB genes in ovarian Cancer tissue
The relative amount of CGB transcripts was evaluated
between control and cancerous ovarian tissue. CGB gene
cluster expression was analyzed using RT-qPCR in two
assays: CGB1–2 and CGB3–9. In the first we examined
CGB1 and CGB2 genes expression, and in the second,
we quantified transcript levels arising from the most
transcriptionally active CGB genes found in placental
and choriocarcinoma tissue – CGB3/CGB9, CGB5,
CGB6/CGB7, CGB8 [18, 19].
The analysis of relative expression of CGB genes, which
can encode chorionic gonadotropin beta subunit protein,
varied between control and ovarian tumour samples.
In the case of CGB1 and CGB2 gene transcripts, RT-
qPCR assay showed that more than 20% of analyzed
ovarian tumours expressed CGB1–2, but none of the
control ovarian tissues contained detectable levels of
these genes transcripts (Fig. 1a).
The CGB3–9 assay detected transcripts in all the con-
trol and all ovarian tumours studied. However higher ex-
pression was noted for ovarian tumour group and the
difference was statistically significant (p < 0.01) (Fig. 1b).
The expression level of the analyzed genes did not cor-
relate with either UICC grading or stage of the tumours.
The median of CGB gene expression level, according to
the grade and stage of studied ovarian carcinomas, is
presented in Table 4.
Table 2 Primers (5′→ 3′) and hydrolysis probes for RT-qPCR with the use of SYBR Green and TaqMan assays
Gene Forward primer Reverse primer Hydrolysis probe
SYBR Green SP1 tgaaggaaggggctcggggg ccaggggcaaagtgcccaca n/a
SP3 caggatgtggtaaagtctatgg cttctcacctgtatgtgttcttc n/a
TFAP2A gctgcctcaccagctgtcgg acagggacacggggcctttct n/a
HPRT tgaagagctattgtaatgaccagt caaatccaacaaagtctggc n/a
TaqMan CGB1–2 a ggtccgctgactcyggc b cagcagcagcccctttgac 6FAM-tcactccctgtctcactcccccacg-BBQ
CGB3–9 a gtgtcsagctcacyccagcatccta b agcagcccctggaacatct 6FAM-ccgaggtytaaagccaggtacacsaggc-BBQ
HPRT Human HPRT Gene Assay Cat. No. 05 046 157 001 (Roche Diagnostics, Mannheim, Germany)
a CGB3–9 and CGB1–2 hydrolysis probes were designed and manufactured by Tib Molbiol (Berlin, Germany); b degenerated base code: S-G/C; Y-C/T
Table 1 Histological subtypes and grading of studied ovarian carcinomas
Grading Serous Mucinous Solid appendages Undifferentiated Endometrioid
G1 0 0 0 0 1
G2 5 1 0 0 0
G3 7 0 2 2 1
Total 12 1 2 2 2
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Methylation of CGB genes promoters in control and
ovarian Cancer tissues
Methylation specific PCR was used to establish the
methylation patterns of CGB gene promoter regions. The
allelic CGB genes were again divided into two groups. The
first assay included CGB1 and CGB2 (CGB1–2) and the
second one included CGB3, CGB5 and CGB8 (CGB3–9).
Utilization of MSP allowed discrimination of methylated
and nonmethylated DNA templates as well as quantifica-
tion of methylation levels in the studied groups.
Densitometric analysis of electrophoretically separated
MSP products obtained from CGB1–2 and CGB3–9 pro-
moters demonstrated significant differences between
control and ovarian cancer tissues but only in assays tar-
geting demethylated variants of the promoter. Indeed,
the use of primers recognizing non-methylated DNA
confirmed that ovarian tumour tissues are characterized
by a profoundly higher demethylation level in case of
both CGB1–2 and CGB3–9 gene promoter regions. The
differences were statistically significant (p < 0.01 and p <
0.001, respectively) (Fig. 2).
Statistical analysis of associations between methylation
status of the promoters and expression of CGB genes
did not show any significant correlations. Furthermore,
methylation status of promoters for the analyzed genes
did not correlate with stage or grade of the tumours.
Expression of SP3 and TFAP2A transcriptional factors
differs in control and cancerous ovaries
The availability of transcription factors regulating CGB
genes expression was assessed on RNA level with RT-
qPCR. The assay, designed to quantify relative level of SP1
transcripts, showed that the analyzed groups of samples
did not differ in terms of expression of this transcription
factor (Fig. 3a). However, ovarian tumours were character-
ized by significantly lower SP3 expression than control
ovarian tissue (p < 0.01) (Fig. 3b). Nevertheless, SP1 and
SP3 expression level ratio did not show significant differ-
ences between the two groups (Fig. 3c).
Significant differences between control and ovarian can-
cer tissues were seen for the expression of the TFAP2A
gene, and was higher in case of ovarian cancer tissue (p <
0.001) (Fig. 3d).
Association analysis within the group of ovarian tu-
mours showed that the level of TFAP2A transcripts corre-
lated positively with CGB3–9 gene expression (R = 0.67).
The expression level of these transcription factors did
not correlate with the stage and grade of the tumours.
Table 3 Primers (5′→ 3′) and cycling conditions used in MSP
Primer Name Forward primer Reverse primer Annealing Elongation
CGB1–2_ M gaaattaagttcgaagtcgc cctatcaaccataacgatcg 30 s, 51 °C 30 s, 72 °C
CGB1–2_ NM gtagaaattaagtttgaagttgt cctatcaaccataacaatca 30 s, 47 °C 30 s, 72 °C
CGB3–9_ M tgtttagtttgatggtatcgc atacccgaaacgatcccc 30 s, 58 °C 30 s, 72 °C
CGB3–9_NM aattgtttagtttgatggtattgt aaaatacccaaaacaatcccc 30 s, 55 °C 30 s, 72 °C
DAPK attgggaaggttaaggyggagggaaatttggt ccccaaacraaacaatccccaaaaccacattccta 30 s, 59 °C 60 s, 72 °C
M methylated variant, NM nonmethylated variant
A B
Fig. 1 Relative expression level of (a) CGB1–2, (b) CGB3–9 transcripts in healthy ovary and ovarian tumor tissue measured using RT-qPCR
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Discussion
It has been known for some time that, not only
gynecological cancers but also other tumours of many
different origin are capable of secreting hCG and espe-
cially its free beta subunit. However, the regulation of
CGB genes expression as well as the role of hCGβ protein
in tumorigenesis have not been satisfactorily established.
It has been shown that both epigenetic and transcrip-
tion factors might regulate the genes encoding human
chorionic gonadotropin beta subunit. However, most of
the studies regarding CGB expression have been con-
ducted on trophoblasts cells or choriocarcinoma cell
lines in vitro and not epithelial carcinomas.
In this study we have investigated the mechanisms
regulating the expression of human chorionic gonado-
tropin beta subunit in non-trophoblastic cancer, specific-
ally epithelial ovarian cancer tissues. For this purpose
two complementary assays were adopted. First we ana-
lyzed epigenetic changes of CGB promoter fragments
and in the next step we determined the expression levels
of key transcription factors involved in the regulation of
CGB expression. The data obtained were correlated with
CGB mRNA levels. CGB genes expression on RNA level
Table 4 Median of relative CGB genes expression level
according to the grade and stage of studied ovarian carcinomas
CGB1–2 CGB3–9
Grade G1 0,00E+ 00 1,92E-05
G2 0,00E+ 00 3,88E-05
G3 0,00E+ 00 4,70E-05
Stage I 0,00E+ 00 1,92E-05
II 0,00E+ 00 6,35E-05
III 0,00E+ 00 4,40E-05
IV 0,00E+ 00 6,57E-06
A B
C D
Fig. 2 Methylation status of (a, b) CGB1–2 and (c, d) CGB3–9 promoter sequence in healthy ovary and ovarian tumor tissue analyzed using MSP
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was analyzed in two groups. The first included CGB1
and CGB2 genes, the second consisted of the more tran-
scriptionally active genes reported in placental studies:
CGB3/CGB9, CGB5, CGB6/CGB7 and CGB8 [19, 27].
The results of our experiments demonstrated that both
control and malignant ovarian tissues produce chorionic
gonadotropin beta subunit transcripts. The expression of
CGB3–9 genes was not only confirmed for all studied
samples, but was also shown to be significantly higher in
cancer than control ovarian tissue. This is consistent
with previous reports on the prevalence of the transcrip-
tional activity of CGB3–9 genes in malignant tissue
when compared to benign changes or healthy tissues
[19, 27]. CGB1 and CGB2 genes were detected to be
transcriptionally active only in 20% of tested ovarian
cancer tissues and at the lowest level across all tested
CGB genes of the cluster. It is only recently, due to
novel sensitive molecular techniques, that it has become
possible to establish that these are active genes and not,
as previously considered, pseudogenes [27–29]. In fact
we previously demonstrated the presence of CGB1 and
CGB2 transcripts in ovarian carcinomas [27]. Still, little
is known about regulation of these genes expression and
transcription factors assumed to regulate CGB1 and
CGB2 expression were predicted using in silico analysis
tools [30].
Associations between the expression of CGB genes
and epigenetics have hitherto been studied only in nor-
mal placental tissue and it has been known for some
time that the genome of placental tissue is characterized
by a higher degree of hypomethylation compared to
other healthy tissues; the CGB gene coding region is no
exception to this [11–13, 31, 32]. Our previous study
showed that CGB3–9 are the most transcriptionally
A B
C D
Fig. 3 Relative expression level of (a) SP1, (b) SP3, (c) SP1/SP3, and (d) TFAP2A transcripts in healthy ovary and ovarian tumor tissue measured
using RT-qPCR
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active CGB genes in placenta and are hypomethylated.
However, so are CGB1 and CGB2 promoter regions.
Here we have shown a similar pattern of hypomethylation
and increased transcription of CGB genes in ovarian can-
cer tissue. Notably transcription of CGB1 and CGB2 was
detected in 20% of ovarian cancer samples. Additionally,
our experiments revealed that the degree of methylation
of CGB promoter regions correlates with the level of CGB
transcripts in chorionic tissue and placenta. Thus, epigen-
etic changes may be considered a factor contributing to
pregnancy failure [13]. By implication it may be speculated
that the induction of CGB gene cluster methylation could
contribute to the decrease in hCGβ expression by tu-
mours, which may be advantageous to cancer patients.
The manner in which epigenetics influences carcinogen-
esis varies among different carcinomas. However, DNA
hypomethylation or demethylation was the initial epigen-
etic aberration recognized in human tumours [33] and is
still extensively studied as a phenomenon associated with
the development and survival of cancer cells. In this con-
text our results show that ovarian cancers are character-
ized by demethylation of the CGB genes compared to
control ovary tissues.
There were no significant correlations between methyla-
tion status and expression level of particular CGB genes.
This fact might be the consequence of the adopted
methods. Even though RT-qPCR is a highly sensitive and
accurate method, methylation specific PCR (MSP) is a
semi-quantitative technique. Thus, combining data ob-
tained using these two methods in the statistical analysis
might not have yielded significant differences, although
differences between healthy ovary and cancerous tissue
were evident in both assays.
It has been shown, that for CGB genes transcription in
placenta, the most important seems to be 360 nucleo-
tides long 5’UTR region with binding sites of transcrip-
tion factors such as: SP1, SP3 and AP2, which regulate
basal CGB expression [13, 22, 26, 34, 35]. Our previous
results revealed strong correlations between TFAP2A
transcripts and CGB1–9 as well as CGB3–9 mRNA
levels in term placenta [13]. In the present study con-
ducted on cancer tissue, we confirm the significance of
TFAP2A, as its higher expression in cancer tissues in
contrast to normal ovary was noted. What is more
strong positive correlation between the amount of the
factor’s mRNA and that of CGB3–9 in this group has
been shown.
The influence of SP1 and SP3 expression on CGB ex-
pression in cancer is very difficult to assess. The results
showed that healthy ovaries and ovarian cancers did not
differ in terms of SP1 transcription factor expression.
On the other hand, ovarian tumours were characterized
by significantly lower level of SP3 transcripts. The ex-
pression of these transcription factors did not correlate
with CGB transcriptional activity. Still, it is known that
SP1 and SP3 are factors which can extend opposite ef-
fects on CGB genes expression in trophoblast. There-
fore, interpretation of the results obtained for cancers
may not be so straightforward [22, 26]. Nevertheless, it
cannot be excluded that similar mechanisms may regu-
late CGB gene expression during both pregnancy and in
cancer.
Parallels between pregnancy development and cancer
have been shown before. Malignant and trophoblastic
cells share the ability to escape apoptosis, migrate and
invade surrounding tissues while evading a host immune
response [36]. Because of a common mechanisms influ-
encing CGB genes expression in pregnancy and cancer
shown in our studies, it can be expected that regulation
of these processes might share some common features.
Indeed, the results of the present study showed that,
similar to the placenta, the expression of CGB genes in
ovarian cancer strongly correlates with TFAP2A expres-
sion. Additionally both tissues are characterised by the
demethylation of CGB promotors.
Further studies on the common pathways of CGB genes
transcription regulation in trophoblast and malignant cells
can lead to the development of novel diagnostic approaches
for the early identification of both pathologies in pregnancy
and cancer.
Conclusions
In ovarian cancers increased expression of human chori-
onic gonadotropin beta subunit is associated with de-
methylation of CGB promoter regions and CGB3–9
expression level strongly correlates with expression of
TFAP2A transcription factor. This seems to point to a
common mechanism of CGB expression regulation in
placenta and ovarian cancer. Furthermore presence of
mRNA arising from CGB1 and CGB2 genes appears to
be a unique feature of a subset of ovarian cancers.
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